JP2006506368A - (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法 - Google Patents

(s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法 Download PDF

Info

Publication number
JP2006506368A
JP2006506368A JP2004544849A JP2004544849A JP2006506368A JP 2006506368 A JP2006506368 A JP 2006506368A JP 2004544849 A JP2004544849 A JP 2004544849A JP 2004544849 A JP2004544849 A JP 2004544849A JP 2006506368 A JP2006506368 A JP 2006506368A
Authority
JP
Japan
Prior art keywords
acid
organic
salt
isomer
chiral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004544849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506368A5 (https=
Inventor
ヌージェント,トーマス・シー
シーメイヤー,ロバート
Original Assignee
ファイザー・プロダクツ・インク
ディーエスエム・ファーマスーティカルズ・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク, ディーエスエム・ファーマスーティカルズ・インコーポレーテッド filed Critical ファイザー・プロダクツ・インク
Publication of JP2006506368A publication Critical patent/JP2006506368A/ja
Publication of JP2006506368A5 publication Critical patent/JP2006506368A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004544849A 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法 Pending JP2006506368A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41905102P 2002-10-16 2002-10-16
PCT/US2003/032275 WO2004035575A1 (en) 2002-10-16 2003-10-10 Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine

Publications (2)

Publication Number Publication Date
JP2006506368A true JP2006506368A (ja) 2006-02-23
JP2006506368A5 JP2006506368A5 (https=) 2006-11-30

Family

ID=32108014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004544849A Pending JP2006506368A (ja) 2002-10-16 2003-10-10 (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法

Country Status (21)

Country Link
US (2) US6861526B2 (https=)
EP (1) EP1551833A4 (https=)
JP (1) JP2006506368A (https=)
KR (1) KR100739901B1 (https=)
CN (1) CN100418964C (https=)
AP (1) AP2005003288A0 (https=)
AR (1) AR041587A1 (https=)
AU (1) AU2003277353B2 (https=)
BR (1) BR0315335A (https=)
CA (1) CA2500635A1 (https=)
EA (1) EA008192B1 (https=)
HR (1) HRP20050328A2 (https=)
IS (1) IS7755A (https=)
MX (1) MXPA05004058A (https=)
PA (1) PA8586601A1 (https=)
PE (1) PE20040777A1 (https=)
PL (1) PL376218A1 (https=)
TN (1) TNSN05111A1 (https=)
UY (1) UY28024A1 (https=)
WO (1) WO2004035575A1 (https=)
ZA (1) ZA200502411B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
LT1713504T (lt) * 2004-01-30 2017-09-11 Zoetis Services Llc Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms
SI1713801T1 (sl) * 2004-02-02 2008-04-30 Pfizer Prod Inc Postopek priprave 1-(2S,3S)-2-benzhidril-N-(5-terc-butil-2-metoksibenzil)kinuklidin-3- amina
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CA3070513C (en) 2010-05-05 2023-01-03 Boehringer Ingelheim International Gmbh A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis
KR20130093012A (ko) 2010-06-24 2013-08-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2731947T3 (en) 2011-07-15 2019-04-23 Boehringer Ingelheim Int SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
CN108341812A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 一种含奎宁环化合物的制备方法
CN108341811A (zh) * 2017-01-23 2018-07-31 科贝源(北京)生物医药科技有限公司 马罗皮坦杂质的制备方法
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
WO2025172911A1 (en) * 2024-02-16 2025-08-21 Teadus Pharmaceuticals Pvt. Ltd A process for the preparation of (2s,3s)-2-benzhydryl- n-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine and pharmaceutically acceptable salts thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511102A (ja) * 1995-07-17 1998-10-27 ファイザー・インコーポレーテッド 1−アザビシクロ[2.2.2]オクタン−3−アミン,2−(ジフェニルメチル)−n−[[2−メトキシ−5−(1−メチルエチル)フェニル]メチル]の分割

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US4680283A (en) 1984-09-26 1987-07-14 Merck & Co., Inc. Analogs of substance P and eledoisin
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
US5138060A (en) 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU657552B2 (en) 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
WO1994004496A1 (en) 1992-08-19 1994-03-03 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5604241A (en) * 1992-10-21 1997-02-18 Pfizer Inc. Substituted benzylaminoquinuclidines as substance P antagonists
JP2656699B2 (ja) 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
JP2656700B2 (ja) 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
CA2149242C (en) * 1992-11-12 1998-08-04 Fumitaka Ito Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders
IL109646A0 (en) 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
MX9706944A (es) 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10511102A (ja) * 1995-07-17 1998-10-27 ファイザー・インコーポレーテッド 1−アザビシクロ[2.2.2]オクタン−3−アミン,2−(ジフェニルメチル)−n−[[2−メトキシ−5−(1−メチルエチル)フェニル]メチル]の分割

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6010011624, J.Med.Chem.,(1975),18(6),p.587−593 *
JPN6010011627, J.Med.Chem.,(1992),35(14),p.2591−600 *

Also Published As

Publication number Publication date
US20050085641A1 (en) 2005-04-21
UY28024A1 (es) 2004-05-31
US20040116704A1 (en) 2004-06-17
BR0315335A (pt) 2005-08-16
AU2003277353B2 (en) 2007-08-09
AR041587A1 (es) 2005-05-26
EA200500650A1 (ru) 2005-10-27
US6861526B2 (en) 2005-03-01
MXPA05004058A (es) 2005-06-08
AU2003277353A1 (en) 2004-05-04
ZA200502411B (en) 2006-05-31
CN100418964C (zh) 2008-09-17
IS7755A (is) 2005-03-17
WO2004035575A8 (en) 2005-05-12
EP1551833A1 (en) 2005-07-13
HK1078087A1 (en) 2006-03-03
HRP20050328A2 (en) 2005-06-30
TNSN05111A1 (en) 2007-05-14
PL376218A1 (en) 2005-12-27
CN1705664A (zh) 2005-12-07
KR20050083764A (ko) 2005-08-26
AP2005003288A0 (en) 2005-06-30
KR100739901B1 (ko) 2007-07-13
PA8586601A1 (es) 2005-02-04
EP1551833A4 (en) 2010-06-02
WO2004035575A1 (en) 2004-04-29
PE20040777A1 (es) 2004-11-20
EA008192B1 (ru) 2007-04-27
CA2500635A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
JP2006506368A (ja) (s,s)−シス−2−ベンズヒドリル−3−ベンジルアミノキヌクリジンの調製方法
WO2009084024A2 (en) A process for the preparation of r-sit agliptin and its pharmaceutically acceptable salts thereof
JPH11505229A (ja) 4−アリール−ピペリジン誘導体を製造する方法
HU216629B (hu) Eljárás 1-aza-biciklo[2.2.2]okt-3-il származékok előállítására
JP2007519710A (ja) 1−(2S,3S)−2−ベンズヒドリル−N−(5−tert−ブチル−2−メトキシベンジル)キヌクリジン−3−アミンの製造方法
Nugent et al. An Efficient Enantiopure Synthesis of a Pivotal Precursor to Substance P Antagonists1
CA2009992A1 (en) 2-amino-7-hydroxytetralin carboxyalkyl ethers
US8524936B2 (en) Manufacturing process for sitagliptin from L-aspartic acid
JPH0757747B2 (ja) フィソスチグミンの製造における中間体として使用されるアルキル化オキシインドールのエナンチオ選択的合成方法
JP2843759B2 (ja) フィゾスチグミンの製造に使用される中間体のエナンチオ選択的合成法
JP4874122B2 (ja) トルテロジンを得るための方法
HK1078087B (en) Process for the preparation of (s,s)-cis-2-benzhydryl-3-benzylaminoquinuclidine
WO2002053537A1 (en) Process for preparing (±) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
JP3982993B2 (ja) 光学活性1−(トリフルオロメチルモノ置換フェニル)エチルアミンの精製方法
CN1989097A (zh) 用于制备非对映异构体富集的化合物的方法
WO2007026373A2 (en) Process for preparing rivastigmine
CN101460446A (zh) 用于生产光学活性1-(氟-、三氟甲基-或三氟甲氧基-取代苯基)烷基胺n-单烷基衍生物的方法
GB2117771A (en) Enantiomers of substituted phenylazacycloalkanes
CN121358709A (zh) 用于制备5-{2-[苄基-(1-(4-羟基苯基)-1-甲基乙基)氨基]-1-羟基乙基}苯-1,3-二醇半富马酸盐的方法
CZ296345B6 (cs) Zpusob výroby hydrochloridu (R)-N-methyl-3-(2-methylfenoxy)-3-fenylpropylaminu (atomoxetinu)
JP2002308836A (ja) 光学活性1−(フルオロフェニル)エチルアミンの精製方法
WO2008146283A2 (en) Novel palonosetron salts and processes for preparation and purification thereof
HU227730B1 (en) Process for the preparation of duloxetine and for their the intermediates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061010

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061010

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100308

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101018